Brought to you by 
Obsidian raises $49.5mm through Series A round
24 Jan 2019
Executive Summary
Obsidian Therapeutics Inc. (developing next-gen cell therapies for cancer) raised $49.5mm through its Series A round. GV led and was joined by Atlas Venture (seed investor), Takeda Ventures, Vertex Ventures, Amgen Ventures, Alexandria Venture Investments, and ShangPharma Investment Group.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
- Vaccines
-
Biotechnology
- Drug Discovery Tools
- Gene Therapy, Cell Therapy
- Large Molecule
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Obsidian raises $49.5mm through Series A round
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice